The U.S. Food and Drug Administration (FDA) has declined to approve Amneal Pharmaceuticals' drug designed to help control symptoms in Parkinson's disease patients for a longer duration, citing inadequate safety data.
July 3 - The U.S. Food and Drug Administration has declined to approve Amneal Pharmaceuticals'
Amneal has been looking to rake in more than $500 million in revenues from its specialty business by 2027.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Wearable movement-tracking data identify Parkinson’s disease years before clinical diagnosis - Nature MedicineUK Biobank motion tracking data show increased performance as compared to symptoms and genetic and lifestyle factors in identifying prodromal Parkinson's disease in the general population CynthiaSandor4 UKDRI
続きを読む »
Smartwatches may provide early Parkinson's diagnosisTracking speed of movement might provide a diagnosis up to seven years ahead of symptoms, a study suggests.
続きを読む »
$2.9 million gene therapy for severe hemophilia is approved by FDAU.S. health regulators have approved a gene therapy for the most common form of hemophilia.
続きを読む »
The Best Red Light Therapy Devices (and Why They Work)This FDA-approved treatment helps improve skin health and vitality while decreasing the appearance of acne, scars and signs of aging. RSRecommends
続きを読む »
Watson Grinding explosion 'could have been prevented', new fed report saysA deadly explosion that rocked northwest Houston in January 2020 could have been prevented with better planning and safety training, the federal agency responsible for investigating chemical incidents said in a new report released this week.
続きを読む »
Tubing, other recreation restrictions lifted on Clear Creek in Jefferson CountyJUST IN TIME: Right before the Fourth of July holiday, Jefferson County officials on Monday lifted restrictions that previously limited recreational water activities on Clear Creek due to safety concerns.
続きを読む »